Xie Hui, Li Youwei, Yang Jie, Tan Yuwei, Xu Jin, Yang Xiao
Hepatobiliary Pancreatic Surgery, Deyang People's Hospital, Deyang, Sichuan, China.
Front Oncol. 2025 Jul 28;15:1560210. doi: 10.3389/fonc.2025.1560210. eCollection 2025.
Primary hepatocellular carcinoma (PHC) requires advanced diagnostic and therapeutic strategies. While transcatheter arterial chemoembolization (TACE) is a cornerstone treatment, efficacy assessment remains challenging.
We retrospectively analyzed 90 PHC patients treated with TACE. Serum DCP levels were measured pre-treatment and at 1, 4, and 8 weeks post-treatment. Treatment response was evaluated using mRECIST criteria.
Low DCP patients (≤40 mAU/mL) showed significantly higher response rates (53.3%) compared to high DCP (>300 mAU/mL, 30.0%, p<0.05). The hazard ratio for treatment failure was 1.62 (95% CI: 1.09-2.23, p<0.01) per unit increase in log-transformed DCP. Median overall survival was 24.5 months for low DCP versus 12.6 months for high DCP patients (log-rank p<0.001).
DCP serves as a robust biomarker for predicting TACE efficacy, enabling personalized treatment strategies in PHC management.
原发性肝细胞癌（PHC）需要先进的诊断和治疗策略。虽然经动脉化疗栓塞术（TACE）是一种基石性治疗方法，但疗效评估仍然具有挑战性。
我们回顾性分析了90例接受TACE治疗的PHC患者。在治疗前以及治疗后1周、4周和8周测量血清DCP水平。使用mRECIST标准评估治疗反应。
低DCP患者（≤40 mAU/mL）的反应率（53.3%）显著高于高DCP患者（>300 mAU/mL，30.0%，p<0.05）。经对数转换的DCP每增加一个单位，治疗失败的风险比为1.62（95%CI：1.09-2.23，p<0.01）。低DCP患者的中位总生存期为24.5个月，而高DCP患者为12.6个月（对数秩检验p<0.001）。
DCP可作为预测TACE疗效的有力生物标志物，有助于在PHC管理中制定个性化治疗策略。
